Abstract
Intrinsic or acquired chemoresistance represents the main obstacle to the successful treatment of cancer patients. Several mechanisms are involved in multidrug resistance: decreased uptake of hydrophilic drugs, increase of energy dependent efflux, alteration of the redox state, alteration of apoptotic pathways, and modification of the tumor microenvironment. In recent years, several types of nanoparticles have been developed to overcome these obstacles and improve the accumulation and release of drugs at the pathological site. In this review, we describe the main mechanisms involved in multidrug resistance and the nanovehicles which have been proposed to target specific aspects of this phenomenon.
Keywords: Cancer, chemoresistance mechanisms, drug delivery, miRNA/siRNA delivery, nanoparticles, mitoxantrone, daunorubicin.
Current Medicinal Chemistry
Title:Drug Delivery Nanoparticles in Treating Chemoresistant Tumor Cells
Volume: 24 Issue: 42
Author(s): Giuseppina Barrera, Martina Daga, Benedetta Ferrara, Chiara Dianzani, Stefania Pizzimenti, Monica Argenziano, Roberta Cavalli and Francesco Trotta*
Affiliation:
- Department of Chemistry, University of Turin, Via Pietro Giuria 7, 10125 Turin,Italy
Keywords: Cancer, chemoresistance mechanisms, drug delivery, miRNA/siRNA delivery, nanoparticles, mitoxantrone, daunorubicin.
Abstract: Intrinsic or acquired chemoresistance represents the main obstacle to the successful treatment of cancer patients. Several mechanisms are involved in multidrug resistance: decreased uptake of hydrophilic drugs, increase of energy dependent efflux, alteration of the redox state, alteration of apoptotic pathways, and modification of the tumor microenvironment. In recent years, several types of nanoparticles have been developed to overcome these obstacles and improve the accumulation and release of drugs at the pathological site. In this review, we describe the main mechanisms involved in multidrug resistance and the nanovehicles which have been proposed to target specific aspects of this phenomenon.
Export Options
About this article
Cite this article as:
Barrera Giuseppina, Daga Martina, Ferrara Benedetta, Dianzani Chiara, Pizzimenti Stefania, Argenziano Monica, Cavalli Roberta and Trotta Francesco*, Drug Delivery Nanoparticles in Treating Chemoresistant Tumor Cells, Current Medicinal Chemistry 2017; 24 (42) . https://dx.doi.org/10.2174/0929867323666161205122225
DOI https://dx.doi.org/10.2174/0929867323666161205122225 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Defining Features and Exploring Chemical Modifications to Manipulate RNAa Activity
Current Pharmaceutical Biotechnology Mitochondria-targeted Resveratrol Derivatives Act as Cytotoxic Pro-oxidants
Current Pharmaceutical Design Ligands and Therapeutic Perspectives of Adenosine A2A Receptors
Current Pharmaceutical Design Flavonoid Derivatives Targeting BCR-ABL Kinase: Semisynthesis, Molecular Dynamic Simulations and Enzymatic Inhibition
Current Topics in Medicinal Chemistry Insights Into Effects of Ellagic Acid on the Nervous System: A Mini Review
Current Pharmaceutical Design Hollow Inorganic Nanoparticles as Efficient Carriers for siRNA Delivery: A Comprehensive Review
Current Pharmaceutical Design Headache in Multiple Sclerosis - Pharmacological Aspects
Current Pharmaceutical Design Status of Programmed Death Ligand 1 (PD-L1) by Immunohistochemistry and Scoring Algorithms
Current Drug Targets Hepatocyte Growth Factor and Macrophage-stimulating Protein “Hinge” Analogs to Treat Pancreatic Cancer
Current Cancer Drug Targets Directing Hypoxic Tumor Microenvironment and HIF to Illuminate Cancer Immunotherapy's Existing Prospects and Challenges in Drug Targets
Current Drug Targets Should we Target Allergen Protease Activity to Decrease the Burden of Allergic Airway Inflammation?
Inflammation & Allergy - Drug Targets (Discontinued) Mechanisms Underlying Chemopreventive Effects of Flavonoids via Multiple Signaling Nodes within Nrf2-ARE and AhR-XRE Gene Regulatory Networks
Current Chemical Biology Phenylbutyric Acid: Simple Structure - Multiple Effects
Current Pharmaceutical Design 1,3,5-Triazine Analogs: A Potent Anticancer Scaffold
Current Signal Transduction Therapy Mechanisms to Inhibit Matrix Metalloproteinase Activity: Where are we in the Development of Clinically Relevant Inhibitors?
Recent Patents on Anti-Cancer Drug Discovery Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Pathogenesis and Treatment Options
Current Vascular Pharmacology Evolutioninthe Pharmacogenetics and Pharmacogenomics of Inflammatory Bowel Disease - Order Slowly Rises from the Chaos
Current Pharmacogenomics Activated Cancer Therapy Using Light and Ultrasound - A Case Series of Sonodynamic Photodynamic Therapy in 115 Patients Over a 4 Year Period
Current Drug Therapy Clinical Use of Therapies Targeting Tumor Vasculature and Stroma
Current Cancer Drug Targets Applications of 211At and 223Ra in Targeted Alpha-Particle Radiotherapy
Current Radiopharmaceuticals